Revvity
Anastasia Kaufman is a Senior Scientist I at Revvity since May 2023, with previous experience as a Senior Scientist I and Scientist 2 at Horizon Discovery from January 2021 to May 2023, and as a Scientist at Inscripta, Inc. from July 2019 to September 2020. During tenure at Inscripta, Kaufman contributed to gene editing projects in iPSCs, developed SOPs, and established assays for measuring gene editing efficacy. Earlier, as a PhD Candidate at the UCLA Department of Molecular and Medical Pharmacology from September 2014 to June 2019, research focused on improving gene editing outcomes in hematopoietic stem cells, while supervising undergraduate researchers. Prior roles included a Laboratory Research Assistant and Undergraduate Research Fellow at UCLA, investigating DNA alterations in cancers and metabolic phenotypes, respectively. Kaufman holds a PhD in Molecular and Medical Pharmacology from the David Geffen School of Medicine at UCLA and a Bachelor's degree in Biochemistry from UCLA.
This person is not in any teams
This person is not in any offices
Revvity
8 followers
At Revvity, “impossible” is inspiration, and ""can't be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Learn more at www.revvity.com